Evaluation of [18F]FluciclatidePositron Emission Tomography For the Prediction of Response to Pazopanib In Patients With Metastatic Renal Cell Carcinoma: An Exploratory Study

Trial Profile

Evaluation of [18F]FluciclatidePositron Emission Tomography For the Prediction of Response to Pazopanib In Patients With Metastatic Renal Cell Carcinoma: An Exploratory Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Fluciclatide F-18 (Primary)
  • Indications Renal cell carcinoma
  • Focus Diagnostic use
  • Most Recent Events

    • 27 Feb 2016 Status changed from recruiting to discontinued as per Clinicaltrials.gov record.
    • 02 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top